These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31734986)

  • 1. [Alanine aminotransferase normalization with antiviral therapies in hepatitis B].
    Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2019 Oct; 27(10):741-747. PubMed ID: 31734986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    Chen J; Xu CR; Xi M; Hu WW; Tang ZH; Zang GQ
    J Viral Hepat; 2017 Jul; 24(7):573-579. PubMed ID: 28107601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
    Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between alanine aminotransaminase level and hepatocellular carcinoma in antiviral therapy of chronic viral hepatitis].
    Zhang L; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):838-841. PubMed ID: 31941238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognosis and management of inactive HBV carriers.
    Invernizzi F; Viganò M; Grossi G; Lampertico P
    Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.
    Feld JJ; Ayers M; El-Ashry D; Mazzulli T; Tellier R; Heathcote EJ
    Hepatology; 2007 Oct; 46(4):1057-70. PubMed ID: 17654702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.
    Oliveri F; Coco B; Ciccorossi P; Colombatto P; Romagnoli V; Cherubini B; Bonino F; Brunetto MR
    World J Gastroenterol; 2008 Oct; 14(40):6154-62. PubMed ID: 18985805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
    Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
    Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.
    Jacobson IM; Washington MK; Buti M; Thompson A; Afdhal N; Flisiak R; Akarca US; Tchernev KG; Flaherty JF; Aguilar Schall R; Myers RP; Subramanian GM; McHutchison JG; Younossi Z; Marcellin P; Patel K
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1087-1094.e2. PubMed ID: 28215615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.
    Lai CL; Yuen MF
    Ann Intern Med; 2007 Jul; 147(1):58-61. PubMed ID: 17606962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimal timing significance and clinical implications for the treatment of chronic HBV-infected patients with normal ALT].
    Fan YX; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):985-987. PubMed ID: 34865342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal.
    Gao S; Fan YC; Zhao J; Sun FK; Han J; Zhao ZH; Wang K
    Liver Int; 2014 Aug; 34(7):e229-37. PubMed ID: 24112455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.
    Wong RJ; Nguyen MT; Trinh HN; Chan C; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Torres S; Yang J; Liu B; Garcia RT; Bhuket T; Baden R; Levitt B; da Silveira E; Gish RG
    J Viral Hepat; 2017 Dec; 24(12):1089-1097. PubMed ID: 28581644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.